Lupin has informed about submission of a Press Release as regards receipt of 'Establishment Inspection Report' from the USFDA, at the company's Pithampur (Unit 3) (Indore) facility. This is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.